Patents by Inventor Anne Galy

Anne Galy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11993781
    Abstract: The present invention relates to a method for obtaining stable pseudotyped lentiviral particles including a heterologous gene of interest, comprising the following steps: a) transfecting at least one plasmid in appropriate cell lines, wherein said at least one plasmid comprises the gene of interest, the rev. gag and pol genes, and a sequence coding for an ERV syncytin, wherein the rev, gag and pol genes are retroviral genes; b) incubating the transfected cells obtained in a), so that they produce the stable pseudotyped lentiviral particles in the supernatant; and c) harvesting and concentrating the stable lentiviral particles obtained in b). The present invention also relates to a method to transduce immune cells using lentiviral vectors pseudotyped with an ERV syncytin glycoprotein. The method can be performed on non-stimulated blood cells or on cells stimulated briefly with IL7, and the cells can be expanded. The stable pseudotyped lentiviral particles obtained are particularly useful in gene therapy.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: May 28, 2024
    Assignees: Institut National de la Santé et de la Recherche Médicale
    Inventor: Anne Galy
  • Publication number: 20230203537
    Abstract: The present invention relates to a method for obtaining stable pseudotyped lentiviral particles including a heterologous gene of interest, comprising the following steps: a) transfecting at least one plasmid in appropriate cell lines, wherein said at least one plasmid comprises the gene of interest, the rev, gag and pol genes, and a sequence coding for an ERV syncytin, wherein the rev, gag and pol genes are retroviral genes; b) incubating the transfected cells obtained in a), so that they produce the stable pseudotyped lentiviral particles in the supernatant; and c) harvesting and concentrating the stable lentiviral particles obtained in b). The present invention also relates to a method to transduce immune cells using lentiviral vectors pseudotyped with an ERV syncytin glycoprotein. The method can be performed on non-stimulated blood cells or on cells stimulated briefly with IL7, and the cells can be expanded.
    Type: Application
    Filed: September 6, 2022
    Publication date: June 29, 2023
    Inventor: Anne GALY
  • Publication number: 20210198636
    Abstract: The invention relates to a pharmaceutical composition for targeting drug delivery including gene delivery to lung tissue, comprising at least a therapeutic drug or gene associated to a syncytin protein, and its use in the prevention and/or treatment of lung diseases, in particular in gene therapy of said diseases using lentiviral vector particles or lentivirus-like particles pseudotyped with syncytin protein.
    Type: Application
    Filed: October 19, 2018
    Publication date: July 1, 2021
    Applicants: Genethon, Institut National de la Santé et de la Recherche Médicale, Université d'Evry val d'Essonne
    Inventors: Anne Galy, Youna Coquin, Maxime Ferrand
  • Publication number: 20200261589
    Abstract: The invention relates to a pharmaceutical composition for targeting drug delivery including gene delivery to regenerating muscle tissue, comprising at least a therapeutic drug or gene, associated to a syncytin protein, and its use in the prevention and/or treatment of muscle injuries or diseases, in particular in gene therapy of said diseases using lentiviral vector particles or lentivirus-like particles pseudotyped with syncytin protein.
    Type: Application
    Filed: October 19, 2018
    Publication date: August 20, 2020
    Applicants: Genethon, Institut National de la Santé et de la Recherche Médicale, Université d'Evry val d'Essonne
    Inventors: Anne Galy, Maxime Ferrand
  • Publication number: 20190300902
    Abstract: The present invention relates to a method for obtaining stable pseudotyped lentiviral particles including a heterologous gene of interest, comprising the following steps: a) transfecting at least one plasmid in appropriate cell lines, wherein said at least one plasmid comprises the gene of interest, the rev. gag and pol genes, and a sequence coding for an ERV syncytin, wherein the rev, gag and pol genes are retroviral genes; b) incubating the transfected cells obtained in a), so that they produce the stable pseudotyped lentiviral particles in the supernatant; and c) harvesting and concentrating the stable lentiviral particles obtained in b). The present invention also relates to a method to transduce immune cells using lentiviral vectors pseudotyped with an ERV syncytin glycoprotein. The method can be performed on non-stimulated blood cells or on cells stimulated briefly with IL7, and the cells can be expanded. The stable pseudotyped lentiviral particles obtained are particularly useful in gene therapy.
    Type: Application
    Filed: April 21, 2017
    Publication date: October 3, 2019
    Inventor: Anne GALY
  • Publication number: 20060257380
    Abstract: The present invention relates to the use of small interfering RNAs (siRNAs) for silencing gene expression in antigen-presenting cells such as dendritic cells, in particular for immunomodulatory purposes.
    Type: Application
    Filed: September 19, 2002
    Publication date: November 16, 2006
    Applicants: Inst.Nat. De La Sante Et De La Recherche MED, Genethon, Institut Gustave Roussy
    Inventors: Anne Galy, Diego Laderach, Daniel Compagno
  • Patent number: 5681559
    Abstract: The present invention provides a simple and reliable means for isolating populations of hematopoietic cells enriched for stem cell activity on the basis of possession of high CD34 cell surface antigen density ("CD34hi"). CD34.sup.hi cell preparations are useful, for example, for drug discovery efforts, for reconstituting hematopoiesis in an animal lacking a functioning hematopoietic system, and for gene therapies.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 28, 1997
    Assignee: Systemix, Inc.
    Inventors: David DiGiusto, Anne Galy